New cancer drug PRO1160 tested in advanced cancers – trial ends early
NCT ID NCT05721222
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma. The goal was to find a safe dose and see if the drug shrinks tumors. The trial was stopped early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRO1160 (GEN1160)
What this could lead to
If successful, this could point toward a new treatment option for certain advanced cancers that have not responded to other therapies.
What could go wrong
This trial was terminated early, so results are limited. It is an early-phase study, so safety and effectiveness are not yet established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital of Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
-
City of Hope Comprehensive Cancer Center - Duarte
Duarte, California, 91010, United States
-
Cleveland Clinic - Euclid Hospital
Cleveland, Ohio, 44195, United States
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Levine Cancer Center
Charlotte, North Carolina, 28204, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Montefiore Medical Center - Montefiore Hospital
The Bronx, New York, 10467, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
-
START Mountain Cancer Center
West Valley City, Utah, 84119, United States
-
Sarah Cannon Research Institute - Nashville
Nashville, Tennessee, 37203, United States
-
The City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California, 92618, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63110, United States